- Clinical Pharmacology
- HIV Clinical Pharmacology
- ACTG Pharmacology Specialty Laboratory
- Adherence Pharmacology Program
- Global HIV Clinical Pharmacology QA
- UB-UZ AIDS HRTP
- ECMC – Immunodeficiency Services
- PGY2 HIV/Infectious Diseases Residency Program
- ACTG Clinical Trials Unit
- TPRC - Developmental Center for AIDS Research
- NIDA Drug Interaction Studies
- The TDM Registry and Associated Research
- Laboratory for Antimicrobial Pharmacodynamics
- Cardiovascular Pharmacotherapy
- Center for Human Experimental Therapeutics
- Transplantation Immunosuppressive Clinical Pharmacology
- HIV Clinical Pharmacology
Bioanalysis and Pharmacogenomics
The TPRC conducts research that often includes bioanalytical methods such as liquid chromatography for analyte seperation and mass spectrometry for detection of compounds/drugs. The TPRC has international recognition for the quality of the analytical work that it conducts. The Director, Dr. Gene D. Morse is a recognized international leader in HIV Clinical Pharmacology research and training, and he currently directs multiple NIH-funded programs. These initiatives include an AIDS International Training and Research Program from the NIH Fogarty International Center, a NIAID Global HIV Clinical Pharmacology Quality Assurance Pharmacology Program with a Core Reference Laboratory, and an AIDS Clinical Trials Group (ACTG) Pharmacology Specialty Laboratory.
Dr. Morse is a member of the UB Clinical and Translational Sciences Research Center (CTRC)/CTSA Operations Committee and a Co-Director of the University of Rochester Clinical and Translational Science Institute (CTSI) Key Function, UNYTE Translational Research Network. The TPRC Core lab has been conducting clinical and translational research since the beginning of the HIV epidemic and was one of the initial laboratories that established the NIH ACTG in 1987 and is a New York State-approved laboratory for therapeutic drug monitoring. The TPRC has increased research activities in the area of Hepatitis C virus (HCV) infection and is engaged in multiple projects that are investigating antiviral regimens in patients with HIV/HCV co-infection.
The Laboratory Scientific Manager, Robin DiFrancesco, also has international recognition as a leader in analytical methods and quality laboratory systems assessment. Ms. Difrancesco has recently worked with leaders from the Society for Quality Assurance on a Rapid Response Task Force that prepared a response to the Draft Guidance for Industry on Bioanalytical Method Validation. Dr. Qing Ma, a faculty member and current K08 awardee is focused in pharmcokinetics and pharmacodynamics associated with HIV-associated neurocognition changes and also conducts clinical pharmacogenomics research.